Response

Affiliations

¹ Department of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo, Brazil (DFJ); Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, CA, USA (MS and RZ); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA (JJL and CW); The University of Texas MD Anderson Cancer Center, Houston, USA (JM); American Society of Clinical Oncology, Alexandria, VA, USA (RLS).

Comment

Denis L Jardim et al. J Natl Cancer Inst. 2016.

. 2016 Feb 24;108(3):djw001.

doi: 10.1093/jnci/djw001. Print 2016 Mar.

¹ Department of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo, Brazil (DFJ); Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, CA, USA (MS and RZ); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA (JJL and CW); The University of Texas MD Anderson Cancer Center, Houston, USA (JM); American Society of Clinical Oncology, Alexandria, VA, USA (RLS).

No abstract available

Comment on

Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.
Jardim DL, Schwaederle M, Wei C, Lee JJ, Hong DS, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. Jardim DL, et al. J Natl Cancer Inst. 2015 Sep 15;107(11):djv253. doi: 10.1093/jnci/djv253. Print 2015 Nov. J Natl Cancer Inst. 2015. PMID: 26378224 Free PMC article.
RE: Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.
Freidlin B, Korn EL. Freidlin B, et al. J Natl Cancer Inst. 2016 Feb 24;108(3):djv430. doi: 10.1093/jnci/djv430. Print 2016 Mar. J Natl Cancer Inst. 2016. PMID: 26912650 Free PMC article. No abstract available.